- Home
- GHRS vs INBX Comparison
GHRS vs INBX Comparison
Compare GHRS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | INBX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GHRS | INBX |
|---|---|---|
| Price | $21.36 | $105.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $41.38 | ★ $150.00 |
| AVG Volume (30 Days) | 260.1K | ★ 612.3K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $10.67 | $12.80 |
| 52 Week High | $24.66 | $155.29 |
Technical Indicators
Market Signals| Indicator | GHRS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 47.94 |
| Support Level | $12.41 | $69.30 |
| Resistance Level | $22.88 | $153.14 |
| Average True Range (ATR) | 1.42 | 13.39 |
| MACD | -0.10 | -4.17 |
| Stochastic Oscillator | 61.56 | 14.75 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.